One factor limiting the therapeutic efficacy of cord blood (CB) hematopoietic progenitor cell (HPC) transplantation is the low cell dose of the graft. This is associated with an increased incidence of delayed or failed engraftment. Cell dose can be increased and the efficacy of CB transplantation potentially improved, by ex vivo CB expansion before transplantation. Two ex vivo CB expansion techniques were compared: (1) CD133 þ selection followed by ex vivo liquid culture and (2) co-culture of unmanipulated CB with bone-marrow-derived mesenchymal stem cells (MSCs). Ex vivo culture was performed in medium supplemented with granulocyte colony-stimulating factor, stem cell factor and either thrombopoietin or megakaryocyte growth and differentiation factor. Expansion was followed by measuring total nucleated cell (TNC), CD133
Introduction
Umbilical cord blood (CB) is becoming an important source of hematopoietic progenitor cell (HPC) support following myeloablative and non-myeloablative therapies. [1] [2] [3] [4] [5] [6] A major limitation to the therapeutic efficacy of CB is the low cell dose available for transplantation, which can lead to delayed engraftment and higher rates of graft failure. 1, 3, 5, [7] [8] [9] Two approaches being investigated to increase the total number of CB cells include the transplantation of two CB units [10] [11] [12] [13] and the ex vivo expansion of CB before transplantation.
There is evidence of functional and phenotypic heterogeneity within the HPC compartment. [14] [15] [16] One concern associated with ex vivo expansion is that short-term reconstituting, lower-'quality' HPC will be expanded at the expense of long-term reconstituting, higher-'quality' HPC, thereby significantly impacting on the hematopoietic reserve of the graft. 17 Evidence, primarily in animal models, suggests that this may occur under certain conditions. Compromised long-term repopulating activity following ex vivo expansion has been reported in fetal sheep, [18] [19] [20] nonhuman primate, 21 feline 22 and mouse models. [23] [24] [25] Clinically, while the absence of durable engraftment from ex vivo-expanded CD34 þ cells has once been reported, 26 durable engraftment has been reported in patients who received expanded autologous peripheral blood progenitor cells as the sole source of hematopoietic support following high-dose therapy. 19 This observation, together with other evidence, suggests that the primitive HPC compartment, [27] [28] [29] [30] [31] [32] HPC homing after transplantation 33 and basic biological and genetic characteristics of HPC, 34 are preserved following ex vivo expansion.
Currently, several approaches exist for ex vivo HPC expansion. The majority of static liquid culture ex vivo expansion systems first require the isolation of CD34 þ or CD133 þ HPC from fresh or frozen hematopoietic tissue. [35] [36] [37] Positively selected CD34 þ or CD133 þ cells are subsequently incubated in culture medium supplemented with granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF) and thrombopoietin (TPO). 38 Clinically, liquid ex vivo expansion of CD34 þ CB cells was reported to increase total nucleated cells (TNC) by 56-fold and the total number of CD34 þ cells by fourfold. 38 A two-step, 14-day ex vivo CB expansion protocol was subsequently developed and yields 4400-fold increase in TNC and 420-fold increase in CD34 þ cells.
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Ex vivo liquid CB expansion removes the primitive HPC from the hematopoietic microenvironment and relies on the addition of exogenous growth factors to prevent apoptosis and stimulate proliferation, potentially driving differentiation at the expense of self-renewal. An alternative approach for ex vivo expansion is the co-culture of CB cells with components of the hematopoietic microenvironment. The hematopoietic microenvironment contains the putative stem cell 'niche' and is composed of hematopoietic and non-hematopoietic (cellular and extracellular) components, 40, 41 thought to provide the complex molecular cues that direct HPC self-renewal and proliferation and regulate the differentiation and maturation of hematopoietic progeny. [42] [43] [44] [45] [46] [47] This would be consistent with the observation that ex vivo contact with stromal components of the hematopoietic microenvironment preserves hematopoietic stem cell activity. [48] [49] [50] [51] [52] [53] One component of the hematopoietic microenvironment, mesenchymal stem cells (MSCs), can be isolated as plastic adherent cells from a variety of fetal and adult tissues. [54] [55] [56] [57] In addition to providing an alternative (co-culture) strategy for CB expansion, allogeneic MSC coadministration has been shown to promote engraftment of human CD34
þ cells in NOD/SCID mice and fetal sheep, [57] [58] [59] [60] [61] and MSCs have been shown to have clinical immunomodulatory activity that may impact on graft-versus-host disease in transplant patients. 59, [62] [63] [64] [65] [66] [67] [68] [69] CB-MSC co-culture does not require the isolation of CD34 þ or CD133 þ cells before expansion, minimizing manipulation and loss of HPC. McNiece et al. 56 have demonstrated a 10-to 20-fold increase in TNC, a seven-to 18-fold increase in committed progenitor cells (colonyforming cells), a two-to five-fold increase in primitive progenitor cells (high proliferative potential colony-forming cells) and a 16-to 37-fold increase in CD34 þ cells, using an MSC co-culture expansion technique. In our current clinical CB expansion protocols, CD133 þ cells are isolated before culture. 38 Despite the 450-fold expansion in TNC, the upfront loss of CD34 þ and CD133 þ cells owing to the positive selection procedure is significant, reducing the final cell dose available for transplant. Thus, we sought to develop a CB expansion procedure, which would maximize the expanded cell dose available for transplantation. Here, we compared the efficacy of an ex vivo liquid culture expansion protocol that required CD133 þ isolation before expansion, with a CB-MSC coculture expansion protocol that did not require CB manipulation before expansion.
Materials and methods

CB units
Pre-and post-ex vivo liquid expansion, TNC, CD133 þ , CD34 þ and colony-forming unit (CFU) data were obtained from 11 frozen CB units processed for either validation studies or clinical use as described below. An additional three frozen CB units were cultured using the same liquid culture method to evaluate the yield of the more primitive cobblestone area (CA)-forming cells (CAFC). CB units were thawed and at least 10% of the mononuclear cell (MNC) fraction co-cultured with MSC as described below. Data from these partial CB units were each normalized to provide an estimate of the numbers of TNC, CD133 þ , CD34 þ , CFU and CAFC following ex vivo CB-MSC co-culture expansion and compared to the liquid culture results.
Ex vivo liquid expansion of CD133
þ -selected CB cells After signing informed consent, eight patients were enrolled on University of Texas MD Anderson Cancer Center Protocol 02-407 and had one entire frozen CB unit expanded using a liquid culture expansion technique. Cells were infused following myeloablative therapy. An additional three CB units were also used in initial validation studies (total 11 CB units). For each CB unit, CD133 þ cells were selected using the CliniMACS device and AC133 Reagent (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer's instructions. The CD133 þ -selected cells were incubated in a 100 ml Teflon-coated culture bag (American Fluoroseal Corp., Gaithersburg, MD, USA) at 371C in a total volume of 50 ml of ex vivo expansion medium: aMEM (HyClone, Logan, UT, USA) supplemented with 50 mg/ml gentamicin sulfate (Irvine Scientific, Santa Ana, CA, USA), 2 mM L-glutamine (HyClone, Logan, UT, USA) and 10% (v/v) irradiated fetal bovine serum (FBS) (HyClone, Logan, UT, USA) and containing 100 ng/ml each of G-CSF (Amgen, Thousand Oaks, CA, USA), SCF (Amgen) and either megakaryocyte growth and differentiation factor (Kirin Brewery Co., Ltd, Tokyo, Japan) or TPO (R&D Systems, Minneapolis, MN, USA).
After 7 days of culture, the 50 ml cell suspension was added to 750 ml of ex vivo expansion medium in a 1 l Teflon-coated culture bag (American Fluoroseal Corp.) and culture continued for an additional 7 days (14 days total) at which time they were harvested and assayed for TNC, CFU, CD133 þ and CD34 þ . As detailed previously, specifically to investigate the proportion of CAFC wk2-6 present in pre-and post-CD133 þ selection samples and post-ex vivo liquid expansion culture, part (approximately 70%) of an additional three frozen CB units were subjected to CD133 þ selection using MidiMACS apparatus and AC133 Reagent (Miltenyi Biotec Inc., Auburn, CA, USA) and cultured in 10 ml of ex vivo expansion medium in 25 cm 2 flasks. After 7 days of culture, a 2 ml aliquot of the cell suspension was added to 30 ml ex vivo expansion medium and cultured for an additional 7 days (14 days total). At day 14, cells were harvested and assayed for CAFC.
MSC preparation
MSCs were isolated from fresh bone marrow from healthy donors obtained under University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) Protocol Lab02-630. Briefly, bone marrow MNCs were collected from the interface generated following Histopaque (Sigma Chemical Co., St Louis, MO, USA) density separation and washed once in MSC culture medium: aMEM supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin sulfate, 2 mM L-glutamine and 20% (v/v) FBS. The MNC from a 10 ml bone marrow aspirate were cultured in a 75 cm 2 culture flask at a concentration of 1-5 culture flasks at 10% of a CB unit per flask. Co-culture was performed for 7 days at 371C. After 7 days, the 50 ml of culture medium containing non-adherent cells were removed and replaced with 50 ml of fresh expansion medium and culture continued for an additional 7 days (14 days total). Two milliliter aliquots of the non-adherent cells were cultured with 30 ml of fresh expansion medium in 75 cm 2 flasks and culture continued for an additional 7 days (14 days total), as previously described for ex vivo liquid expansion. At day 14, non-adherent cells from both cultures were harvested and assayed to yield TNC, CFU, CD133 þ , CD34 þ and CAFC data. Also, at day 14 adherent cells from the CB-MSC co-culture flasks were removed by trypsinization and assayed for the presence of CD133 þ and CD34 þ cells by flow cytometry to provide a measure of hematopoietic progenitors remaining associated with the MSC monolayer.
Flow cytometric analysis
Flow cytometric analyses were performed to (1) determine the proportion of CD133 þ and CD34 þ cells in pre-and post-CD133 þ -selected positive samples of CB and following the ex vivo expansion processes, and (2) confirm the phenotype of bone marrow-derived serially passaged and frozen and thawed MSC.
Pre-and post-CD133 þ -selected positive fractions of CB cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD45 (BD Biosciences Pharmingen, San Jose, CA, USA), phycoerythrin (PE)-conjugated anti-CD133/2 (AC141, Miltenyi Biotec Inc., Auburn, CA, USA) and allophycocyanin-conjugated anti-CD34 (8G12) (BD Biosciences Pharmingen, San Jose, CA, USA) according to the manufacturer's instructions. For ex vivoexpanded hematopoietic cells, samples were stained with anti-CD45-FITC-and PE-conjugated anti-CD133/2, or PE-conjugated anti-CD34 (8G12) (BD Biosciences Pharmingen, San Jose, CA, USA) owing to FL3 and FL4 autofluorescence. The proportion of CD133 þ and CD34 þ cells was expressed both as a percentage of TNC (used subsequently to calculate CD133 þ and CD34 þ numbers) and as a percentage of a 'lymphocyte gate', which specifically contained the stem cell activity.
MSCs were assayed for CD31, CD34, CD45, CD73, CD80, CD90, CD105, CD166, HLA-ABC (I) and HLA-DR (II) expression according to the manufacturer's instructions. With the exception of anti-CD105-FITC (Serotec, Kidlington, Oxford, UK), all antibodies were purchased from BD Biosciences (San Jose, CA, USA).
CFU assay
For each sample assayed, duplicate CFU assays were performed. Briefly, CFU assays were performed in semisolid methylcellulose culture medium (MethoCult, StemCell Technologies, Vancouver, BC, Canada) supplemented with 50 ng/ml SCF, 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF), 20 ng/ml interleukin (IL)-3, 20 ng/ml IL-6, 20 ng/ml G-CSF, 3 U/ml EPO and containing 30% (v/v) FBS (MethoCult GF þ H4435, StemCell Technologies), as per the manufacturer's instructions. CFU assays were cultured for 21 days in a fully humidified, 371C, 5% CO 2 in air atmosphere. Colonies were defined as clusters consisting of X40 cells and were enumerated using a dissecting microscope and dark field illumination. CFU frequencies and total CFU numbers per CB unit were determined.
CAFC assay
The frequency of CAFC in samples was determined by limiting dilution analysis (LDA), as described originally. 70, 71 Cultures were plated and refed weekly with CAFC medium: Iscove's modified Dulbecco's medium (Gibco Invitrogen Corp., Grand Island, NY, USA) supplemented with 10% (v/v) each of FBS (HyClone, Logan, UT, USA) and horse serum (HS, Gibco Invitrogen Corp., Grand Island, NY, USA), 100 U/ml penicillin and 100 mg/ml streptomycin sulfate (Gibco Invitrogen Corp., Grand Island, NY, USA), 2 mM L-glutamine (HyClone, Logan, UT, USA), 10 À5 M hydrocortisone-21-hemisuccinate (Sigma Chemical Co., St Louis, MO, USA), and containing 10 ng/ ml IL-3 (R&D Systems, Minneapolis, MN, USA) and 20 ng/ml G-CSF (Neupogen Filgrastim, Amgen). CAFC microwell cultures were scored 'positive' or 'negative' at weekly intervals for the presence of CAs using an inverted microscope. Assay of CA present in culture at 2 weeks of culture (CAFC wk2 ) is considered to provide a measure of relatively mature HPC, whereas assay of CA persisting in culture for 6 weeks (CAFC wk6 ) is considered to provide a measure of relatively primitive HPC. 72, 73 The proportion of 'negative' wells at each cell concentration was used in a Poisson-based LDA calculation to determine CAFC frequency and the numbers of CAFC (CAFC wk2 and CAFC wk6 ) per CB unit were calculated.
Statistical analysis
Means were compared using the Student's two-sample t-test (Microsoft Excel, Microsoft Corp.) and significance was assumed at Pp0.05.
Results
CB units
The cellular composition of the thawed CB units (n ¼ 11) is shown in The CD133 þ selection process also recovered approximately 20% of CD34 þ cells and increased the proportion of the TNC that were CD34 þ from 0.370.1% preselection to 24.974.1% post-selection. When a 'lymphocyte gate' was applied to the TNC population, the proportion of CD34 þ cells was increased from 0.670.1% pre-selection to 77.674.5% post-selection. Approximately 40% of CFU and o1% of CAFC activity was recovered from the CB units following the CD133 þ selection process, further demonstrating the marked loss of HPC that is associated with the selection process. These data underscore the need to develop CB expansion strategies that do not require positive selection before culture.
Expansion of CD133
þ -selected CB cells Fourteen days of ex vivo liquid culture of the CD133 þ -selected CB cells generated 4800 Â 10 6 TNC, a significant (440-fold, P ¼ 0.00002) increase from the o20 Â 10 6 TNC input into the culture system. (Table 1) The number of CFU generated during the 14-day ex vivo liquid culture was significantly increased (20- Expansion of non-selected CB cells by MSC co-culture MSC products. Phenotypically, MSC expressed CD73, CD90, CD105, CD166 and HLA-ABC (I) and did not express CD31, CD34, CD45, CD80 and HLA-DR (II). This phenotype was conserved through repeated cell passage and following freezing and thawing (data not shown).
CB-MSC co-culture. Interactions between MSC and primitive hematopoietic progenitors contained in the thawed, washed CB sample were observed by the presence of CAs (areas of phase-distinct cells beneath the MSC monolayer) and foci of hematopoiesis on the surface of the MSC (Figure 1) . A significant (sixfold, P ¼ 0.002) increase over the initially input TNC was observed after 14 days of CB-MSC co-culture (Table 1) . This expansion data is consistent with that obtained from a limited number (n ¼ 2) of clinical-scale CB-MSC co-culture experiments (unpublished data), where approximately four-and ninefold increases in TNC were observed. Thus, approximately 10 10 TNC could be generated from thawed, washed CB units initially containing 1-2 Â 10 9 TNC. Flow cytometry also revealed a significant (31-fold, P ¼ 0.003) increase in CD133 þ cell from an initial 5 Â 10 6 in thawed, washed CB units to approximately 150 Â 10 6 after 14 days of CB-MSC co-culture. Similarly, flow cytometry revealed a significant (eightfold, P ¼ 0.003) increase in CD34 þ cells from an initial 14 Â 10 6 in thawed, washed CB units to approximately 112 Â 10 6 after 14 days of CB-MSC co-culture. Further, CFU assay revealed a significant (4200-fold, P ¼ 0.001) increase in CFU from approximately 1 Â 10 6 in thawed, washed CB units to 4200 Â 10 6 after 14 days of CB-MSC co-culture. CAFC assay revealed a significant (450-fold, P ¼ 0.007) increase in CAFC wk2 from an initial 1.5 Â 10
6 to approximately 75 Â 10 6 after 14 days of CB-MSC co-culture, although a significant (95%) reduction (P ¼ 0.001) in CAFC wk6 from an initial 10 Â 10 6 to approximately 0.5 Â 10 6 was observed. These data suggest that during the 14-day CB-MSC co-culture, the significant increase in TNC number and the numbers of CD133 þ , CD34
þ , CFU and CAFC wk2 was, at least in part, at the expense of the CAFC wk6 .
Adherent cells. Trypsinization of the adherent layer remaining after 14 days of CB-MSC co-culture and 
Discussion
Preliminary clinical trials using CD34 þ -or CD133 þ -selected CB cells expanded in a liquid culture system have resulted in time to neutrophil engraftment of 25-35 days. 38 In recipients of unmanipulated CB products, there is growing clinical evidence suggesting that patients who receive higher doses of TNC 3 and CD34 þ cells 3, 74 experience faster engraftment than do patients who receive lower TNC and CD34 þ CB doses. This stimulated our interest in strategies that might improve the expansion capability of CB above that generated with liquid cultures, with the goal of achieving neutrophil engraftment in 15 days, or less, as typically occurs in unrelated bone marrow or peripheral blood HPC transplant recipients. It can be postulated that MSC co-culture with CB cells without the need for an initial positive selection step (and the associated loss of HPC) might produce a CB graft with better engraftment potential. One report where fresh CB cells were co-cultured with MSC 56 further stimulated our interest in this strategy.
Data presented here demonstrate that the ex vivo coculture of non-selected CB cells with MSC generated superior TNC and HPC expansion than did the ex vivo liquid culture of CD133 þ -selected CB cells. The improved TNC and HPC expansion observed during the CB-MSC co-culture would be consistent with the observation that ex vivo contact with stromal components of the hematopoietic microenvironment preserves hematopoietic stem cell activity. [48] [49] [50] [51] [52] [53] MSC co-culture with CB units (containing approximately 10 9 TNC) resulted in estimated CB TNC numbers that were 410-fold higher (approximately 10 10 TNC, P ¼ 0.0005) than liquid ex vivo expansion of CD133 þ -selected CB cells (o10 9 TNC) ( Figure 2 ). CB-MSC co-culture also generated a significantly greater output of CFU (425-fold, P ¼ 0.0002), CD133
þ cells (47-fold, P ¼ 0.01), CD34
þ cells (414-fold, P ¼ 0.003), CAFC wk2 (4200-fold, P ¼ 0.0002) and CAFC wk6 (444-fold, P ¼ 0.009) than did ex vivo liquid culture of CD133 þ -selected CB. These data demonstrate that the expansion of TNC and HPC appears superior using CB-MSC co-culture (without CD133 þ selection) when compared to the use of þ cell doses achieved following CB-MSC co-culture may also reduce engraftment time. 38 The possibility of using multiple cords, one of which is transplanted unmanipulated, the other of which is co-cultured with MSC before transplant, may yield a combined graft that contains both HPC responsible for long-term repopulation (largely derived from the unmanipulated CB unit) and HPC responsible for short-term repopulation (derived from the ex vivo CB-MSC co-cultured CB unit). Such a combination of donor material may potentially provide the recipient with more rapid (short-term) and durable (long-term) engraftment.
In neither ex vivo culture system (liquid or co-culture) was there expansion of more primitive CAFC wk6 . In both cases, the expansion of the more mature hematopoietic HPC appeared to be, at least in part, at the expense of the more primitive CAFC wk6 population. However, during 14-day ex vivo CB-MSC co-culture, a greater proportion (5%) of the initial CB CAFC wk6 population was maintained than was observed during 14-day ex vivo liquid culture (0.1%). The CAFC wk6 population may represent higher-quality HPC within the expanded CB sample and may be the cells most responsible for long-term, sustained hematopoiesis following transplantation. The fact that their numbers were not completely exhausted during the expansion process would be consistent with previous reports. [27] [28] [29] A clinical trial to assess the safety and efficacy of CB expansion using an MSC co-culture strategy will be conducted.
